Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
Martin HaluzíkMohammed E Al-SofianiAlice Y Y ChengFelipe LauandLydie Melas-MeltJulio RosenstockPublished in: Diabetes, obesity & metabolism (2024)
iGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.